Skip to main content
Top
Published in: Rheumatology International 2/2012

01-02-2012 | Original Article

Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis

Authors: Yousra Ibn Yacoub, Bouchra Amine, Assia Laatiris, Rachida Bensabbah, Najia Hajjaj-Hassouni

Published in: Rheumatology International | Issue 2/2012

Login to get access

Abstract

We aimed to evaluate diagnosis delay and its impact on disease in terms of activity, functional disability, and radiographic damage in Moroccan patients with ankylosing spondylitis (AS). We recruited 100 Moroccan patients who fulfilled New York Classification criteria for AS. Diagnosis delay was defined as the interval between the first symptom of AS and the moment of a correct diagnosis. Disease activity was evaluated by the bath ankylosing spondylitis disease activity index (BASDAI), functional status by the bath ankylosing spondylitis functional index (BASFI), and radiographic damage by the bath ankylosing spondylitis radiologic index (BASRI). Measurements of spinal mobility were assessed. The average age at disease onset was 28.56 ± 10.9 years. Of the patients, 16% had juvenile-onset AS. Disease duration was 9.5 ± 6.8 years, and the average of diagnosis delay was 4.12 ± 3.99 years. There were no differences in diagnosis delay according to the age at onset, educational level, or the presence of extra-articular involvement. Our patients had altered functional ability. Patients with late diagnosis (>5 years) had statistically significant higher structural damage (BASRI) and severe limited spinal mobility. There was no correlation between diagnosis delay and the activity of disease. Few studies focused on diagnostic delay and its impact in patients with AS. It is necessary in our context to establish an early diagnosis taking into account the high frequency of severe functional disability in Moroccan AS.
Literature
1.
go back to reference Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462PubMedCrossRef Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462PubMedCrossRef
2.
go back to reference Khan MA (2002) Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 61(3):3–7 Khan MA (2002) Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 61(3):3–7
3.
go back to reference Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S (2006) Definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann Rheum Dis 65(11):1518–1520PubMedCrossRef Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S (2006) Definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann Rheum Dis 65(11):1518–1520PubMedCrossRef
4.
go back to reference Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Het Mielants et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3):755–765CrossRef Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Het Mielants et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3):755–765CrossRef
5.
go back to reference Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H (2003) Grassnickel Letal. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRef Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H (2003) Grassnickel Letal. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRef
6.
go back to reference Aggarwal R, Malaviya AN (2009) Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes–an Indian perspective. Clin Rheumatol 28(3):327–331PubMedCrossRef Aggarwal R, Malaviya AN (2009) Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes–an Indian perspective. Clin Rheumatol 28(3):327–331PubMedCrossRef
7.
go back to reference El Mansouri L, Bahiri R, Abourazzak FZ, Abouqal R, Hajjaj-Hassouni N (2009) Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int 29:1423–1429PubMedCrossRef El Mansouri L, Bahiri R, Abourazzak FZ, Abouqal R, Hajjaj-Hassouni N (2009) Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int 29:1423–1429PubMedCrossRef
8.
go back to reference Moll JM (1987) New criteria for the diagnosis of ankylosing spondylitis. Scand J Rheumatol Suppl 65:12–24PubMedCrossRef Moll JM (1987) New criteria for the diagnosis of ankylosing spondylitis. Scand J Rheumatol Suppl 65:12–24PubMedCrossRef
9.
go back to reference Rostom S, Benbouazza K, Amine B, Bahiri R, Lazrak N, Abouqal R, Guillemin F, Hajjaj-Hassouni N (2009) Psychometric evaluation of the Moroccan version of the Bath ankylosing spondylitis functional index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol (in press) Rostom S, Benbouazza K, Amine B, Bahiri R, Lazrak N, Abouqal R, Guillemin F, Hajjaj-Hassouni N (2009) Psychometric evaluation of the Moroccan version of the Bath ankylosing spondylitis functional index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol (in press)
10.
go back to reference Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol 43:750–757CrossRef Haywood KL, Garratt AM, Jordan K, Dziedzic K, Dawes PT (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol 43:750–757CrossRef
11.
go back to reference Kaya T, Gelal F, Gunaydin R (2006) The relationship between severity and extent of spinal involvement and spinal mobility and physical functioning in patients with ankylosing spondylitis. Clin Rheumatol 25:835–839PubMedCrossRef Kaya T, Gelal F, Gunaydin R (2006) The relationship between severity and extent of spinal involvement and spinal mobility and physical functioning in patients with ankylosing spondylitis. Clin Rheumatol 25:835–839PubMedCrossRef
12.
go back to reference Dernis-Labous E, Messow M, Dougados M (2003) Assessment of fatigue in the management of patients with ankylosing spondylitis. Rheumatology 42:1523–1528PubMedCrossRef Dernis-Labous E, Messow M, Dougados M (2003) Assessment of fatigue in the management of patients with ankylosing spondylitis. Rheumatology 42:1523–1528PubMedCrossRef
13.
14.
go back to reference Feldtkeller E, Erlendsson J (2008) Definition of disease duration in ankylosing spondylitis. Rheumatol Int 28(7):693–696PubMedCrossRef Feldtkeller E, Erlendsson J (2008) Definition of disease duration in ankylosing spondylitis. Rheumatol Int 28(7):693–696PubMedCrossRef
15.
go back to reference Liao Z, Gu J, Huang F, Lin Z, Zhao L, Yu B (2009) Verification of Berlin algorithm for diagnosing undifferentiated spondyloarthropathy patients in Chinese population. Joint Bone Spine 76(2):146–149PubMedCrossRef Liao Z, Gu J, Huang F, Lin Z, Zhao L, Yu B (2009) Verification of Berlin algorithm for diagnosing undifferentiated spondyloarthropathy patients in Chinese population. Joint Bone Spine 76(2):146–149PubMedCrossRef
16.
go back to reference Rudwaleit M, van der Heijde D, Khan MA et al (2004) How to diagnose axial spondyloarthropathies early. Ann Rheum Dis 63:535–543PubMedCrossRef Rudwaleit M, van der Heijde D, Khan MA et al (2004) How to diagnose axial spondyloarthropathies early. Ann Rheum Dis 63:535–543PubMedCrossRef
17.
go back to reference Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD (2005) Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 53(3):445–451PubMedCrossRef Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD (2005) Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 53(3):445–451PubMedCrossRef
18.
go back to reference Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCrossRef Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCrossRef
19.
go back to reference Gorman JD, SackK E, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRef Gorman JD, SackK E, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRef
20.
go back to reference Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 59(6):822–832PubMedCrossRef Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 59(6):822–832PubMedCrossRef
Metadata
Title
Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis
Authors
Yousra Ibn Yacoub
Bouchra Amine
Assia Laatiris
Rachida Bensabbah
Najia Hajjaj-Hassouni
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1635-7

Other articles of this Issue 2/2012

Rheumatology International 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine